Next-Generation Sequencing for High-Throughput RNA Interference Screens

  • Toby M. WardEmail author
  • Anna-Maria Jegg
  • Elizabeth Iorns


Ribonucleic acid interference (RNAi) screening has emerged as an indispensable genetic research tool, allowing determination of phenotypic effects after silencing entire suites of genes. As the catalog of fully sequenced genomes and transcriptomes grows, production of small interfering/short-hairpin RNA libraries that target every gene in a particular cell, tissue, or organism is achievable, allowing high-throughput “genome-wide” RNAi screening. This technology has been embraced by cancer biologists and has been used to analyze a myriad of phenotypic effects of genetic loss of function in human cancers.

A basic RNAi screening scheme includes silencing of a panel of genes in a cell population, followed by identification of a phenotypic change (in cancer research, this might include cell death, cell invasion, sensitivity to therapeutics). Upon identification of cells exhibiting the phenotype of interest, it is necessary to determine which specific shRNAs are responsible. Previously, this process was laborious, requiring tedious DNA extraction, PCR amplification, and individual cloning and sequencing of PCR amplicons to determine the specific shRNA(s) harbored by cells.

With the advent of next-generation sequencing (NGS), identification of individual shRNAs harbored by cells has been revolutionized. NGS allows rapid and specific identification of shRNA oligomers present in the cell(s) of interest and requires minimal amounts of source material. This chapter will describe the use of NGS in RNAi screens with a focus on cancer biology and provide resources for those interested in pursuing NGS-powered RNAi screens.


RNAi screen Next-generation sequencing Massively parallel sequencing In vivo screen High-throughput screen shRNA Loss-of-function screen 


  1. 1.
    Carthew RW. Molecular biology. A new RNA dimension to genome control. Science. 2006;313(5785):305–6. Epub 2006/07/22.PubMedCrossRefGoogle Scholar
  2. 2.
    Tomari Y, Zamore PD. Perspective: machines for RNAi. Genes Dev. 2005;19(5):517–29. Epub 2005/03/03.PubMedCrossRefGoogle Scholar
  3. 3.
    Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806–11. Epub 1998/03/05.PubMedCrossRefGoogle Scholar
  4. 4.
    Boutros M, Ahringer J. The art and design of genetic screens: RNA interference. Nat Rev Genet. 2008;9(7):554–66. Epub 2008/06/04.PubMedCrossRefGoogle Scholar
  5. 5.
    Cullen LM, Arndt GM. Genome-wide screening for gene function using RNAi in mammalian cells. Immunol Cell Biol. 2005;83(3):217–23. Epub 2005/05/10.PubMedCrossRefGoogle Scholar
  6. 6.
    Fuchs F, Boutros M. Cellular phenotyping by RNAi. Brief Funct Genomic Proteomic. 2006;5(1):52–6. Epub 2006/06/14.PubMedCrossRefGoogle Scholar
  7. 7.
    Sims D, Mendes-Pereira AM, Frankum J, Burgess D, Cerone MA, Lombardelli C, et al. High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing. Genome Biol. 2011;12(10):R104. Epub 2011/10/25.PubMedCrossRefGoogle Scholar
  8. 8.
    Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A. 2008;105(26):9053–8. Epub 2008/06/25.PubMedCrossRefGoogle Scholar
  9. 9.
    Iorns E, Ward TM, Dean S, Jegg A, Thomas D, Murugaesu N, et al. Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor. Breast Cancer Res Treat. 2012;135(1):79–91. Epub 2012/04/27.PubMedCrossRefGoogle Scholar
  10. 10.
    Westbrook TF, Martin ES, Schlabach MR, Leng Y, Liang AC, Feng B, et al. A genetic screen for candidate tumor suppressors identifies REST. Cell. 2005;121(6):837–48. Epub 2005/06/18.PubMedCrossRefGoogle Scholar
  11. 11.
    Lin G, Aranda V, Muthuswamy SK, Tonks NK. Identification of PTPN23 as a novel regulator of cell invasion in mammary epithelial cells from a loss-of-function screen of the “PTP-ome”. Genes Dev. 2011;25(13):1412–25. Epub 2011/07/05.PubMedCrossRefGoogle Scholar
  12. 12.
    Campeau E, Gobeil S. RNA interference in mammals: behind the screen. Brief Funct Genomics. 2011;10(4):215–26. Epub 2011/07/28.PubMedCrossRefGoogle Scholar
  13. 13.
    Silva JM, Marran K, Parker JS, Silva J, Golding M, Schlabach MR, et al. Profiling essential genes in human mammary cells by multiplex RNAi screening. Science. 2008;319(5863):617–20. Epub 2008/02/02.PubMedCrossRefGoogle Scholar
  14. 14.
    Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, Li MZ, et al. Cancer proliferation gene discovery through functional genomics. Science. 2008;319(5863):620–4. Epub 2008/02/02.PubMedCrossRefGoogle Scholar
  15. 15.
    Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell. 2009;137(5):835–48. Epub 2009/06/06.PubMedCrossRefGoogle Scholar
  16. 16.
    Zuber J, McJunkin K, Fellmann C, Dow LE, Taylor MJ, Hannon GJ, et al. Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nat Biotechnol. 2011;29(1):79–83. Epub 2010/12/07.PubMedCrossRefGoogle Scholar
  17. 17.
    Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature. 2004;430(7003):1034–9. Epub 2004/08/27.PubMedCrossRefGoogle Scholar
  18. 18.
    Brummelkamp TR, Bernards R. New tools for functional mammalian cancer genetics. Nat Rev Cancer. 2003;3(10):781–9. Epub 2003/10/23.PubMedCrossRefGoogle Scholar
  19. 19.
    Brady T, Roth SL, Malani N, Wang GP, Berry CC, Leboulch P, et al. A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. Nucleic Acids Res. 2011;39(11):e72. Epub 2011/03/19.PubMedCrossRefGoogle Scholar
  20. 20.
    Ustek D, Sirma S, Gumus E, Arikan M, Cakiris A, Abaci N, et al. A genome-wide analysis of lentivector integration sites using targeted sequence capture and next generation sequencing technology. Infect Genet Evol. 2012;12(7):1349–54. Epub 2012/05/23.PubMedCrossRefGoogle Scholar
  21. 21.
    Duncavage EJ, Magrini V, Becker N, Armstrong JR, Demeter RT, Wylie T, et al. Hybrid capture and next-generation sequencing identify viral integration sites from formalin-fixed, paraffin-embedded tissue. J Mol Diagn. 2011;13(3):325–33. Epub 2011/04/19.PubMedCrossRefGoogle Scholar
  22. 22.
    Bassik MC, Lebbink RJ, Churchman LS, Ingolia NT, Patena W, LeProust EM, et al. Rapid creation and quantitative monitoring of high coverage shRNA libraries. Nat Methods. 2009;6(6):443–5. Epub 2009/05/19.PubMedCrossRefGoogle Scholar
  23. 23.
    Sigoillot FD, Lyman S, Huckins JF, Adamson B, Chung E, Quattrochi B, et al. A bioinformatics method identifies prominent off-targeted transcripts in RNAi screens. Nat Methods. 2012;9(4):363–6. Epub 2012/02/22.PubMedCrossRefGoogle Scholar
  24. 24.
    Kaelin Jr WG. Molecular biology. Use and abuse of RNAi to study mammalian gene function. Science. 2012;337(6093):421–2. Epub 2012/07/28.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Toby M. Ward
    • 1
    Email author
  • Anna-Maria Jegg
    • 2
  • Elizabeth Iorns
    • 3
  1. 1.Stanford Cancer Institute, Stanford University School of MedicinePalo AltoUSA
  2. 2.University of Miami Miller School of MedicineMiamiUSA
  3. 3.Science Exchange, Inc.Palo AltoUSA

Personalised recommendations